Kir6.2, a key component of the ATP-sensitive potassium channel (K ATP ), can directly interact with imidazoline derivativesa kind of potential antidiabetic drug. This paper explores the interaction of Kir6.2 with four imidazoline derivatives by using AutoDock and Gromacs programs. The docking results reveal that the binding sites of the four imidazolines are different from each other: Idazoxan lies in a polar active pocket formed by residues H177, G299 and R301; while RX871024 is situated in a hydrophobic pocket composed of residues F168, M169 and I296; as for Efaroxan and Clonidine, residues H175, R177, K67 and W68 constitute the binding pocket. Based on the docking results, the four imidazoline/Kir6.2 complexes with explicit water and infinite lipid bilayer membrane were constructed to perform molecular dynamics (MD) simulation. The results of MD calculation are as follows: dioleoyl phosphatidyl choline bilayer membrane stabilised the structure of these complexes through polar and nonpolar interaction; Idazoxan and RX871024 are stably combined with Kir6.2 in their docking sites; Efaroxan has a minor change in contrast to the docking result; whereas Clonidine has an obvious change compared to docking conformation. The binding sites and interaction modes of these imidazolines with Kir6.2 may provide theoretical support in the pharmacological study of imidazoline drugs.
Introduction
ATP-sensitive potassium (K ATP ) channels couple metabolism to electrical activity in many tissues by regulating K þ fluxes across the cell membrane. K ATP channels play a multitude of functional roles in the organism, such as controlling insulin secretion from pancreatic b-cells, protecting against cardiac stress and brain seizures, mediating ischaemic preconditioning in the heart and brain, and setting the tone of vascular smooth muscle [1, 2] . In glucose-sensing tissues, these channels respond to fluctuating changes in blood glucose concentration, but in other tissues they are activated only under ischaemic conditions or in response to hormonal stimulation [1] . K ATP channels are large hetero-octameric complexes of four pore-forming (Kir6.x) and four regulatory sulphonylurea receptor (SURx) subunits [3] . In most tissues, Kir6.2 serves as the channel pore and SUR appears in several isoforms. As for the K ATP channels in pancreatic b-cells, it has a compact structure, with four SUR1 subunits embracing a central Kir6.2 tetramer in both transmembrane and cytosolic domains, as shown in Figure 1 [4] . Attempts to crystallise Kir6.2 or its C-terminal domains have proved unsuccessful. However, the crystal structures of a putative bacterial Kir channel -KirBac1.1 and the N-and C-terminal domains of its eukaryotic counterparts -Kir3.1 have been solved [5, 6] . The C domains of Kir3.1 and Kir6.2 exhibit a greater sequence identity (48%) than those of Kir6.2 and KirBac1.1 (27%), so that Haider et al. used the proximal N domain and transmembrane domains of KirBac1.1 and the distal N domain and the C domain of Kir3.1 to construct a molecular model of the Kir6.2 tetramer [7, 8] . This model is consistent with a large amount of functional data and further validated by additional site-directed mutagenesis [4] . In this paper, we use the same model of Kir6.2 to identify the binding sites of imidazolines.
Imidazolines are a group of investigational antidiabetic drugs with an antihyperglycaemic but not a hypoglycaemic mode of action, because several compounds of this group enhance insulin secretion only in the presence of a stimulatory glucose concentration [9] . Studies performed over the past few years have suggested that some imidazoline derivatives may stimulate insulin secretion in a more glucose-dependent fashion than sulphonylureas [10, 11] . Thus, the inherent risk of hypoglycaemias caused by the therapeutic use of sulphonylureas may be avoided. Some imidazolines blocking K ATP channels in pancreatic b-cells offer an explanation for their insulinotropic property [9] . Unlike sulphonylureas, which inhibit K ATP channel activity by binding to the regulatory subunit (SUR1) of the b-cells K ATP channel, imidazolines block K ATP channels by directly interacting with the poreforming subunit, Kir6.2 [12, 13] . However, the binding sites and the interaction details of imidazolines with Kir6.2 are still unknown. In this paper, we choose four typical imidazoline derivatives to explore the binding sites and interaction modes with Kir6.2.
The closure of the K ATP channel is facilitated by ATP, and its opening is potentiated by phosphoinositol (PIP2) [7, 14] . Both ATP and PIP2 interact directly with Kir6.2 and the binding sites have already been determined in detail [7, 14] . However, to the best of our knowledge, there is no literature that investigates the binding sites of imidazoline derivatives with Kir6.2.
In recent years, molecular docking and dynamics simulation have been widely used in studying the interaction of drugs with target proteins [15 -18] . To discover how imidazoline derivatives interact with Kir6.2, we performed docking and molecular dynamics (MD) simulation based on the homology model of Kir6.2.
Methods
There have been few studies on the interaction of drugs and ion channel, and still no theoretical research has been related to the imidazoline/Kir6.2 system. Haider et al. and Antcliffe et al. [7, 14] used MD simulation and docking to investigate the binding sites of ATP and PIP2 on Kir6.2. We adopted similar methods to study the imidazolines/ Kir6.2 system.
Ligand docking

Structures of Kir6.2 and ligands
The structural model of Kir6.2 used in this paper is a homology model of the mouse Kir6.2 (residues 32 -358; GenBank D50581) tetramer based on the X-ray crystal structures of KirBac1.1 (PDB id: 1P7B) and the intracellular domains of rat Kir3.1 (PDB id: 1N9P) [7, 14] . This model has been identified by many mutation experiments [4] . We selected four typical imidazoline derivatives widely used in pharmacological experiment, i.e. Efaroxan, Idazoxan, Clonidine and RX871024, as shown in Figure 1 . Their structures were fully optimised at the level of 6-31G(d) by employing the Becke-3-parameter-Lee -Yang -Parr (B3LYP) hybrid density functional theory with Gaussian 03 package [19] . The Gasteiger -Marsili atomic charge was added to ligands and protein. It is also the selection of AutoDock while calculating the empirical free energy function.
Docking set-up
The binding sites of imidazolines with Kir6.2 were identified by automated ligand docking using the program AutoDock v4.0 (http://www.autodock.scripps.edu/), in which the empirical free energy function and the Lamarckian genetic algorithm were employed [20, 21] . All rotational bonds in ligands were set free, while the protein side chains remain fixed. At first, blind docking was applied to each ligand several times, with a grid of 216 £ 216 £ 216 points generated with a grid spacing of 0.375 Å around the central positively charged region. After that, the dimensions of the grids were fixed on 110 £ 210 £ 210 points around the possible binding site, also with a spacing of 0.375 Å between the grid points. This grid space defines the region of the protein in which the ligand searched for the most favourable interactions. Fifty independent docking runs were carried out for each ligand. Results were clustered according to the criterion of 1.0 Å RMSD.
Gromacs dynamics calculation
Model building
Four imidazoline/Kir6.2 complexes obtained by docking were embedded in the centre of a square periodic lipid bilayer consisting of 340 dioleoyl phosphatidyl choline (DOPC) molecules. The overlapped DOPC molecules were deleted and 221 lipid bilayer molecules remained. The resulting systems were solvated with , 120,000 SPC waters and then neutralised by counter ions at random positions. This generated a system of , 406,880 atoms.
Gromacs dynamics set-up
MD simulations of the imidazoline/Kir6.2 systems were carried out with Gromacs-3.3.1-1 suite of programs with the Gromacs force field (http://www.gromacs.org) [22] . We used the PRODRG2 server to parameterise the four imidazoline drugs [23] . All of the complexes were first energy minimised with the steepest descent method; then a 200 ps position restraining simulation was carried out restraining the Kir6.2 by a 1000 kJ/mol Å 2 harmonic constraint to relieve close contacts before the actual simulation; finally, a 3 ns MD simulation was performed. We applied the leap-frog algorithm in the NPT ensemble, and each component, imidazoline, Kir6.2, DOPC, H 2 O and Na þ was separately coupled. The Berendsen temperature coupling and Berendsen pressure coupling (the coupling constants were both set to 0.1) were used to keep the system in a stable environment (300 K, 1 Bar). During these steps, the particle mesh Ewald (PME) method for long-range electrostatics, a 10 Å cut-off for van der Waals interactions, a 9 Å cut-off for Coulomb interaction and the LINCS algorithm for bond constraints were used [24, 25] .
Results and discussion
Docking
Binding sites
The left side of Figure 1 shows the binding sites of the four imidazoline derivatives. Each ligand corresponds to different locations on the Kir6.2 subunit. For clarity, only one binding site of each drug is shown, because the location of the same drug on the four monomers of Kir6.2 is identical. Though the binding sites are different, the locations of each drug on the same monomer are close to each other. Efaroxan and Clonidine lie near to the slide helix of C-terminal, and their binding sites are partially overlapped. The binding site of Idazoxan is located in the intracellular domains, while RX871024 lies in the centre of the channel pore, directly blocking the channel. The AutoDock program also calculates the binding and docking energies. The energy items include intermolecular energy (constituted by van der Waals energy, hydrogen bonding energy, desolvation energy and electrostatic energy), internal energy and torsional energy. The first two items build up docking energy, the first and the third items compose the binding energy. Table 1 Figure 3 shows the lipophilic potential surfaces of residues within 6.0 Å around the ligands. As the colour changes from blue to red, the surface transforms from hydrophilic to hydrophobic. Figure 3(a) shows the surface of Efaroxan, which is located in a hydrophilic surface; Figure 3(b) is the lipophilic potential surface of Clonidine, the hydrophilicity of the surface is weaker than Efaroxan and is more prone to hydrophobic; from Figure 3 (c), it can be seen that the surface around Idazoxan is almost completely hydrophilic; while in Figure 3 (d), all residues around RX871024 are hydrophobic. These results are in accordance with the intrinsic character of the four imidazolines.
From the docking results, four different binding sites were obtained, which were closely related to the structures of these drugs. The experiments did not gain the binding sites about imidazolines with Kir6.2, but the docking provided us with the possible binding sites.
Comparison of the binding sites with PIP2
Haider et al. [14] have already studied the binding site of PIP2 with Kir6.2 in detail. The PIP2 molecule can extend up to , 17 Å on the binding site and directly interact with many residues, including R176, R177, E179, Q299 and R301 at C-terminals, K39 and N41 at N-terminals, and K67 at transmembrane domains [14] . Among the four imidazolines, the binding site of Idazoxan is most similar to that of PIP2. Idazoxan interacts with Kir6.2 by forming three hydrogen bonds with R177, Q299 and R301 and strong van der Waals interaction with R176 and N41 in the binding pocket.
The binding sites of Efaroxan and Clonidine are different from those of Idazoxan but still near to those of PIP2. Some residues like R176, R177 and K67 are in the binding site of PIP2 and the two imidazolines. There are no hydrogen bonds between these two imidazolines and the pocket residues; therefore, the main interaction is nonpolar interaction.
Different from other three imidazolines and PIP2, RX871024 is located in the channel pore of Kir6.2 due to its appropriate size and hydrophobicity. From Figure 2(d) , we can see that the interactional residues including F168, A172 and I296 are all hydrophobic and no hydrogen bonds were formed. It is the hydrophobic interaction that makes RX871024 lie in the channel pore of Kir6.2 and directly block the channel.
The relationship of the function and binding mode
The function of drugs is closely related to their binding sites and interaction mode. Experiments have revealed that imidazolines are potential inhibitors of K ATP channel. RX871024 exhibits an inhibition of 82% at the concentration of 10 mM [26] ; while Efaroxan achieves the same inhibition at the concentration of 100 mM [26] . Idazoxan is the weakest inhibitor among the four imidazolines; its inhibition is lower than 50% even at its maximal concentration. Clonidine, as K ATP inhibitor, shows moderate activity between that of Efaroxan and Idazoxan. Therefore, the order of the inhibitory activity is RX871024 . Efaroxan . Clonidine . Idazoxan [26, 27] . We can explain their inhibitory activity by checking their binding sites. RX871024 is located in the channel pore which is the most active position to inhibit the K ATP ; while the binding site of Idazoxan is far away from the channel pore which is the weakest position; Efaroxan and Clonidine have moderate inhibiting activity on their binding sites which are near to the channel pore.
Imidazolines also stimulate the secretion of insulin, which is mediated by the blockade of Kir6.2. The order of the activity is RX871024 . Efaroxan . Clonidine q Idazoxan [28, 29] . Idazoxan works only at very high concentration. Comparing Efaroxan with RX871024, the latter shows a lower activity at low glucose concentration in stimulating the secretion of insulin, but exhibits a higher activity at high glucose concentration; so RX871024 shows higher potential as an antidiabetic drug [28, 29] . The order of the four imidazolines in stimulating the secretion of insulin and the inhibitory activity of K ATP channel is the same. So we can deduce that the stimulation of insulin secretion is also closely related to the inhibitory activity and the binding sites.
Imidazolines have been studied for the purpose of treating type-1 and type-2 diabetes. In recent years, there have been many new imidazoline medicines investigated, such as BL11282 and NNC77-0074 [30, 31] . But not all imidazolines can be used to treat diabetes because of the b-cell toxicity. The toxicity is due to individual properties of the imidazolines and is different from the sequence of the K ATP channel-blocking and insulin-releasing effect; Efaroxan has no b-cell toxicity, Idazoxan is markedly b-cell toxic and RX871024 has a mediated toxicity [32, 33] . The relationship of toxicity and the binding sites of imidazolines on Kir6.2 is still unclear and further studies are required. Figure 4(a) . The detailed interaction after 3 ns of MD simulation between Kir6.2 and DOPC molecules within 6 Å is displayed in the right panel in Figure 4 (b). For clarity, only the transmembrane region of one monomer of Kir6.2 is shown. The important residues which have polar interaction with DOPC are pointed out. In these systems, though the binding sites of these ligands are far away from the transmembrane region, the lipid bilayer membrane prevented the arbitrary movement between the four monomers of Kir6.2, and they play an important role in stabilising these systems. [14] . Then, the RMSDs of imidazolines relative to Kir6.2 and of protein relative to protein were obtained based on the MD simulation of all the systems to get the information of positional fluctuations, as shown in Figure 5 . From the curve of Figure 5 (a), we can see that Kir6.2 was stabilised by DOPC and the RMSD value of protein relative to protein is about 0.4 nm.
Molecular dynamics simulation
From Figure 5 (a), it can be seen that Efaroxan seems stabilised relative to Kir6.2 at 1.5 ns judging by its RMSD value (, 0.85 nm). By checking the interval conformations, we noticed small changes in the binding mode. All the original hydrogen bonds vanished and were substituted by new ones. For example, Efaroxan and D65 formed one or two new hydrogen bonds which locate in the polar hydrogen of imidazoline ring and carbonyl O in D65.
From Figure 5 (b), we can see that Clonidine has a smooth RMSD curve after 1 ns of simulation and the average RMSD value is 1.05 nm. At the first 0.7 ns, the RMSD curve has a sharp rise and then becomes smooth. When checking the interval conformations, we find that the conformation of Clonidine has changed a lot after 0.7 ns. Though the active pocket is also near the original pocket, new residues interacting with Clonidine are observed (for example I162 and T171). The original hydrogen bond also disappeared at 0.7 ns, and no new hydrogen bond formed. Figure 5 (c) is the RMSD of Idazoxan, the stable conformation formed after 1 ns with the average RMSD value of about 0.25 nm. When examining the interval conformations, it can be seen that at 1 ns the conformation changes a little, then at 1.3 ns, the conformation returns to the original conformation and afterwards. The hydrogen bonds changed a little: one of these on R301 keeps stable in the time of dynamics simulation; other hydrogen bonds changed and were replaced by new ones. The new hydrogen bond forms between the polar hydrogen of imidazoline ring and carbonyl O in E292.
Figure 4(d) shows the RMSD of RX871024; because it is located in the channel pore, the conformation is difficult to change with RMSD value of , 0.25 nm. Just like Idazoxan, the conformation of RX871024 changed a little at the first 1 ns; then it came back to the original conformation. That is to say RX871024 is stably bonded to Kir6.2 on its binding site.
From the RMSDs and interval conformations of imidazolines, we can see that the dynamic simulation is in accordance with the docking results except a visible conformation change in Clonidine. The possible reason is that Clonidine has the lowest docking energy, and the conformation change in dynamic simulation may reach the lower energy domain. In addition we gained the average structure of Kir6.2 and ligands by MD simulation (see Figure 6 ). From the binding site of ligands and the surface of surrounding residues we can see that all the ligands were in proper position with correspondingly stable binding and had little change compared to the docking result. Figure 6 . Focus-view (a) and side-view (b) of the surface around the ligands derived from the average structure of 3ns MD simulation. As the colour changes from green to red, the surface changes from hydrophobic to hydrophilic; Kir6.2 is shown in ribbons and each monomer of it is in a different colour; Ligands are in ball and stick form.
Conclusion
We applied docking and MD simulation to study the binding sites of imidazolines on Kir6. 
